Dose calculator

For veterinarians administering

STELFONTA

How to calculate the correct dose of STELFONTA using the Dose Calculator

  • Accurately measure the tumor (in cm) using a caliper. Make sure you get accurate measurements for length, width and height.
  • Enter your measurements into the Tumor Volume Calculator to determine the volume of the tumor.
  • Calculate the correct dose of STELFONTA once you have the volume of the tumor in cm3, using the Dose Calculator.
  • Draw the required volume into a sterile, Luer-lock syringe with a 23 gauge needle.
  • Inject STELFONTA by inserting the needle into the tumor mass through a single injection site, to minimize leakage, moving the needle in and out in a fanning manner to help ensure the treatment reaches all aspects of the tumor.

Modified ellipsoid with calculation

Tumor Volume Calculator

 cm
x
 cm
x
 cm
x ½
Tumor Volume =

 cm³

Dose Calculator

 kg  

 cm³
x ½
Dosage =

 

 mL

Max. 0.25 mL/kg body weight given in a 5 mL dose; min. 0.1 mL regardless of tumor volume or body weight.

injection top view
injection side view
testimonial

EXPERT TIP from Dr. Justine Campbell

“Measure and measure again – an accurate tumor measurement on the day of treatment (even if measured previously) is key to determining the correct dose of STELFONTA.

Use a Leur-lock syringe to avoid leakage and potential bounce-back.

Administering STELFONTA
Play Video about STELFONTA Mode Of Action video thumbnail
Assessing Complete Response
Stelfonta-Wait-PDF-link-thumbnail
Technical website – Virbac
FDA-CVM WARNING: SEVERE WOUND FORMATION IN HUMANS; EXTENSIVE WOUND FORMATION, MAST CELL DEGRANULATION, AND DEATH IN DOGS DUE TO MAST CELL DEGRANULATION Human Safety
  • Accidental self-injection of STELFONTA® may cause severe wound formation. To decrease the risk of accidental self-injection, sedation of the dog may be necessary (see Dosage and Administration, Human Warnings and Adverse Reactions).
Dog Safety
  • Always administer a corticosteroid, an H1 receptor blocking agent (e.g. diphenhydramine), and an H2 receptor blocking agent (e.g. famotidine) when treating with STELFONTA to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation (see Contraindications and Dosage and Administration).
  • Do not inject STELFONTA into subcutaneous mast cell tumors located above the elbow or hock (e.g. on the body, head, or neck). This may result in accumulation of necrotic debris in the subcutaneous space increasing the risk of systemic adverse reactions, including death, from mast cell degranulation (see Contraindications, Warnings and Adverse Events).
  • Treatment with STELFONTA has been associated with cellulitis and severe tissue sloughing extending away from the treated site resulting in extensive wounds that require additional treatment and prolonged recovery times (see Warnings, Precautions and Adverse Events).
IMPORTANT SAFETY INFORMATION Formation of wounds, possibly extensive, is an intended and likely response to treatment with STELFONTA along with associated swelling, bruising and pain; these wounds are expected to heal. Appropriate pre- and post-treatment medications must be given, including a corticosteroid plus blocking agents for both H1 and H2 receptors, in order to decrease the potential for severe systemic adverse reactions, including death, from mast cell degranulation. Full prescribing information